October 1981

γ-Type Endorphins and Schizophrenia-Reply

Author Affiliations

Maryland Psychiatric Research Center PO Box 3235 Baltimore, MD 21228
Department of Psychiatry University of Chicago 950 E 59th St Chicago, IL 60637

Arch Gen Psychiatry. 1981;38(10):1182-1183. doi:10.1001/archpsyc.1981.01780350116013

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.


—We certainly welcome the additional data provided here supporting the antipsychotic efficacy of DTγE. The authors report that their experience of late, contrary to the initial suspicions, suggests that this endorphin fragment is most efficacious in persons in early schizophrenia who have had short neuroleptic histories. Indeed, the patients we described who were given DTγE were schizophrenics with chronic but active (in no way residual) psychotic symptoms. All of these DTγE-treated patients had previously responded to standard-dose neuroleptic treatment, although they were untreated at the time of DTγE administration. The schizophrenic population defined by Verhoeven et al as responders to DTγE treatment, schizophrenics with psychotic symptoms and drug treatment of short duration, may fall into the new DSMIII category of schizophreniform psychosis. Confirmation of these findings with DTγE, along with the new peptide fragment DEγE, from our and other research centers around the world would be ideal. We remain

First Page Preview View Large
First page PDF preview
First page PDF preview